Enodia Therapeutics acquired Kezar Life Sciences’ Sec61 program assets, including KZR-261, in a deal worth up to $127 million plus royalties.
Written By: Samiksha Jadhav, BPharm
Reviewed By: Pharmacally Editorial Team
Enodia Therapeutics and Kezar Life Sciences have announced a strategic asset acquisition agreement designed to strengthen Enodia’s Sec61-targeted protein degradation platform and support the accelerated development of novel small-molecule inhibitors that selectively block disease-driving proteins at the point of synthesis.
Under the agreement, Enodia has acquired assets related to Kezar’s Sec61-based discovery and development program, including the preclinical candidate KZR-261. The acquisition is expected to deepen Enodia’s understanding of Sec61 selectivity mechanisms while expanding translational and biological insights that may help accelerate future therapeutic development.
According to the terms of the purchase agreement, Kezar will receive upfront payments totaling $1 million, including an initial payment at closing and an additional payment tied to inventory transfer. The company is also eligible to receive development, regulatory, and commercialization milestone payments of up to $127 million, along with tiered royalties on potential future net sales.
The transaction reflects growing industry interest in Sec61 translocon modulation as a promising therapeutic strategy for selectively targeting pathogenic proteins before pathological effects occur. Sec61 modulation has emerged as an area of increasing scientific focus because of its potential applications across immune-mediated diseases and other complex disorders.
Enodia Therapeutics is developing targeted protein degradation therapies designed to inhibit disease-associated proteins during protein synthesis. Its proprietary Sec61 platform selectively modulates the Sec61 translocon while preserving normal physiological protein production. The platform includes multiple Sec61 inhibitor families supported by proteomics datasets, Cryo-EM structural biology capabilities, and specialized cell-line libraries used for machine learning-enabled rational drug design.
Yves Ribeill said Kezar’s preclinical datasets and early discoveries in Sec61 inhibition will strengthen Enodia’s selective targeted protein degradation platform and support faster development decisions across its research programs.
Over the past several years, Kezar Life Sciences has conducted extensive research into the Sec61 translocon, exploring its potential as a therapeutic target for diseases driven by abnormal protein signaling and immune dysfunction. Chris Kirk noted that the agreement allows the scientific progress achieved by Kezar’s team to continue under Enodia’s development efforts while reinforcing the long-term potential of Sec61-directed therapies.
Reference
https://www.sec.gov/Archives/edgar/data/1645666/000162828026017046/kzr-20260306.htm
About the Writer
Samiksha Vikram Jadhav (LinkedIn) is a B. Pharm graduate with a strong academic foundation in pharmaceutical sciences, pharmacology, and drug development. She specializes in pharma market research, with a focused interest in mergers and acquisitions, strategic partnerships, and global pharma and biotech deals. Her work centers on analyzing industry transactions, market positioning, and business strategies, translating complex developments into clear, accurate, and insightful scientific and commercial reporting.